ALXN - Alexion Pharmaceuticals, Inc.
| Previous Close | 112.51 |
| Open | 113.15 |
| Bid | 113.05 x 800 |
| Ask | 114.63 x 1200 |
| Day's Range | 112.47 - 114.35 |
| 52 Week Range | 94.59 - 141.86 |
| Volume | 1,938,423 |
| Avg. Volume | 1,764,485 |
| Market Cap | 25.066B |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | 17.37 |
| EPS (TTM) | 6.52 |
| Earnings Date | Jan 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 146.70 |
- Business Wire
Alexion to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast at 8:00 a.m. Eastern Time (ET).
- Zacks
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
- TipRanks
3 Healthcare Stocks That Are Coming Back to Life
After a stock takes a tumble, wait just a minute before you count it out. While falling share prices could be a sign that a company is under duress, it doesn’t always mean that its growth story has come to an end. After all, a tried and true strategy to turn a profit in the market is to buy low and sell high.Wall Street pros remind investors to take this into consideration when gauging the strength of investments in the healthcare space. As these names rely on only a few key catalysts, all it takes is a single piece of bad news to send shares spiraling downwards. However, the opposite is also true, so one favorable outcome can put a stock right back on track.With this in mind, we used TipRanks’ Stock Screener tool to pinpoint 3 Buy-rated healthcare names that the analysts believe are on the mend after recent nose dives. Here’s the scoop straight from the analysts.BioMarin Pharmaceutical (BMRN) BioMarin has established itself as a key player in the biopharma space, with seven therapies already on the market and several other candidates in development. Despite falling 21% in the first nine months of 2019, SunTrust Robinson analyst Robyn Karnauskas believes that important upcoming catalysts could drive a rebound.The four-star analyst points out that the drop came largely as a result of declining investor confidence in the market potential of its Hemophilia therapy. ValRox, its Hemophilia A candidate progressing through Phase 2, has seen factor levels drop since the first year. However, Karnauskas remains convinced that BMRN can deliver.After conducting a survey to determine if the concerns related to commercialization were valid, the analyst concluded that ValRox could drive significant growth. “Our survey indicates high level of confidence in approval of ValRox, with 100% of doctors expecting approval and steady uptake in severe Hemophilia A patients… Our survey also indicated that doctors are likely to prescribe based on label and do not expect all severe patients to qualify,” she commented.As a result, the analyst believes, “At current values, the stock is trading with little credit to late stage pipeline assets with potential launches in late 2020/2021.” At the peak, Karnauskas estimates the Hemophilia A opportunity to be $1.48 billion.On top of this, its vosoritide therapy for achondroplasia could be a major component of the company’s next leg of growth, with it reporting positive Phase 3 data in December.Based on all of the above, Karnauskas tells investors that she’s siding with the bulls, reiterating a Buy rating on BMRN alongside a $110 price target. Should the target be met, shares will be in for a 24% twelve-month gain. (To watch Karnauskas’ track record, click here)Turning now to the rest of the Street, it appears that other analysts are generally on the same page. With 13 Buys and 3 Holds assigned in the last three months, the consensus rating comes in as a Strong Buy. In addition, the $111.71 average price target puts the upside potential just above Karnauskas’ forecast at 25%. (See BioMarin stock analysis on TipRanks)Alexion Pharmaceuticals (ALXN)Fighting rare diseases like generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) and ALS, Alexion Pharmaceuticals wants to meet the large unmet medical needs of patients globally. Even though the company took a beating in 2019, the Street isn’t giving up on ALXN just yet.While recent data for its candidate to treat PNH, a severe and ultra-rare blood disorder, raised some questions, Wedbush analyst Laura Chico believes its growth prospects are still strong. According to its most recent 8-K filing, total revenue growth is expected to beat the consensus estimate, and Ultomiris is poised to meet its conversion goals. As a result, Chico commented, “we continue to see ALXN as holding a strong competitive position in the complement markets.”It also doesn’t hurt that its neurology franchise is continuing to grow at a steady rate. Over the previous quarter, neurology patients on treatment (gMG/NMOSD) increased 23% to 1,885 patients. Despite the fact that growth slowed by about 5% compared to September/June, management told investors that they are hoping to quadruple their US neurology patient volume by FY25.All of this prompted Chico to conclude, “Overall, we see multiple encouraging updates from ALXN in their upcoming presentation not only on the commercial front, but with several pipeline updates as well. We continue to hold a positive bias on ALXN shares.”To this end, Chico decided to leave the Outperform rating and $149 price target unchanged. At this target, a 32% gain could be in the cards for ALXN over the next twelve months. (To watch Chico’s track record, click here)Like Chico, a majority of the analysts covering ALXN take a bullish approach. With 12 Buys and 3 Holds, the word on the Street is that ALXN is a Strong Buy. The healthcare stock boasts 29% upside potential based on the $145 average price target. (See Alexion stock analysis on TipRanks)Mylan N.V. (MYL)Mylan, one of the largest generic drug makers, has had a rough going, to say the least. Back in May, shares shed 24% of their value in a single day after the company failed to provide an update on the strategic review that had already lasted ten months. More recently, the stock has been range-bound thanks to investor concern regarding a possible cut to Viatris, the combination of Mylan and Pfizer’s Upjohn, as well as its proforma numbers. That being said, some members of the Street still have high hopes for MYL.RBC Capital’s Randall Stanicky thinks that several key factors suggest that MYL has more fuel left in the tank. “We believe buyside expectations are already low with Street proforma models stale while synergies provide support into 2022 stabilization; even on our lowered EBITDA, Newco trades at only 6.6x 2021E EBITDA (<7x even if further cutting EBITDA to $7 billion) while able to support a new dividend yielding about 4%,” he explained.Additionally, the analyst highlights improving corporate governance as well as argues that Viatris’ U.S. generic revenue and limited opioid exposure could help the company “de-couple from generic peers.” He added, “The announced combination of MYL and PFE’s Upjohn off-patent business will further grow and diversify MYL’s revenue base beyond US generics.”Given that it still boasts “one of the best generic/ biosimilar pipelines in the industry”, Stanicky’s bullish thesis remains firmly intact. With this in mind, the analyst maintained an Outperform call. Not to mention, he bumped up the price target from $25 to $27. The price target conveys the analyst’s confidence in MYL’s ability to surge 27% in the next twelve months. (To watch Stanicky’s track record, click here)Looking at the consensus breakdown, we have an almost even split. 4 Buys and 5 Holds received in the last three months add up to a Moderate Buy consensus rating. With a $24.50 average price target, the upside potential is 16%. (See Mylan price targets and analyst ratings on TipRanks)
- Zacks
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
- American City Business Journals
Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure
With competition encroaching, Alexion executives are pushing plans to more than double the company’s product portfolio in the next three years, including at least one “high risk, high reward” drug candidate.
- Zacks
Alexion Pharmaceuticals (ALXN) Dips More Than Broader Markets: What You Should Know
Alexion Pharmaceuticals (ALXN) closed at $112.79 in the latest trading session, marking a -0.99% move from the prior day.
- Zacks
Ultragenyx Provides Preliminary Crysvita 2019 Revenues
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
- Business Wire
Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS
Alexion Pharmaceuticals, Inc. announced the planned initiation of a pivotal Phase 3 study of ULTOMIRIS® (ravulizumab) in ALS.
- Zacks
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
- Zacks
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
- Zacks
Top Ranked Growth Stocks to Buy for January 13th
Top Ranked Growth Stocks to Buy for January 13th
- Kiplinger
11 Samp;P 500 Stocks That Could Soar 20% or More in 2020
Never say never, but it's hard to see stocks follow their amazing 2019 returns for a second straight year.S&P; 500 stocks sent the index a whopping 29% higher in 2020. That's a big deal. Keep in mind that the market's long-term average annual gain comes to about 7.7%, then factor in the tendency for share performance to revert to the mean, and the odds of another boffo year are slim.Indeed, years in which the S&P; 500 rises at least 20% generate an average gain of only 6.6% the following year, according to Bespoke Investment Group.But that doesn't mean investors can't try to replicate 2019's party by seeding their holdings with stocks expected to blow away the broader market. To find stocks primed to outperform, we scoured the S&P; 500 for stocks with expected price gains of at least 20% this year. We supplemented that research by limiting ourselves to stocks that are Buy-rated or better by Wall Street analysts, as well as boast promising fundamentals, attractive valuations and other bullish features.Here, then, are 11 of the best S&P; 500 stocks you can buy for outsize gains in 2020. Based analysts' projected price returns, Wall Street expects these names to rally from 20% to more than 35% this year. SEE ALSO: 20 Top Stock Picks the Analysts Love for 2020
- Benzinga
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
The 38th annual JPMorgan Healthcare Conference, which is tipped off as the biggest health care investment symposium, kicks off Monday in San Francisco, California. From the high and mighty to the smallest ...
- Zacks
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.
- GuruFocus.com
Spiros Segalas Sells Tencent, Trims PayPal Position
Guru's largest sales of the 4th quarter Continue reading...
- Zacks
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
Is (ALXN) Outperforming Other Medical Stocks This Year?
- Zacks
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
- Zacks
Incyte's Application for Pemigatinib Gets EMA's Validation
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
- Zacks
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.
- Zacks
5 Top Value Picks to Counter Recent Stock Market Softness
The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.
- Zacks
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
- Zacks
Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study
Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.
- Investor's Business Daily
This Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed
Shares of Apellis Pharmaceuticals rocketed Tuesday after the biotech company's experimental drug outperformed Alexion Pharmaceuticals' blockbuster, Soliris, in a head-to-head test.
- Bloomberg
Can a Drug's $500,000 Price Withstand Competition?
(Bloomberg Opinion) -- Alexion Pharmaceuticals Inc.’s Soliris may be the most successful rare-disease medicine in history. Its approval in multiple conditions and an annual price tag that can exceed $500,000 propelled the drug to more than $3 billion in sales last year. Now, for the first time, it looks like Alexion’s blockbuster will face serious competition.On Tuesday, Kentucky-based Apellis Pharmaceuticals Inc. published the results of a head-to-head trial between its drug APL-2 and Soliris for use in treating a rare and deadly form of anemia. APL-2 significantly outperformed Soliris, and the results beat the expectations of several Wall Street analysts. If Apellis can get regulatory approval and demonstrate efficacy in other diseases, it could have a blockbuster of its own on its hands.The prospect of APL-2 becoming a genuine money-maker for Apellis sent the company’s shares up more than 20 percent in trading Tuesday. But the outcome of the trial has implications that go beyond the financial fortunes of the the drugmaker and its shareholders. It also sets up a potential test case on whether competition can do something about the out-of-control costs of rare-disease drugs — a very special class of medicines. Rare-disease treatments are exceptionally expensive for a few different reasons. The first is simple math. If patient populations are small, then the price has to be higher for companies to make a decent return. Second, the average health plan or insurer is unlikely to cover multiple people with the same condition, so there’s far less pushback on price than there is for widely used drugs. And finally, because competing for tiny pools of patients isn’t that appealing, drugmakers often end up with markets all to themselves.Put all that together, plus the potential for expanding usage, and you get a blockbuster like Soliris. That’s at least until generic versions arrive, an eventuality Alexion is doing its best to delay for as long as possible. Alexion is also working on switching patients to its newer drug Ultomiris, which gives similar results with much more convenient dosing and has many extra years of patent life. The arrival of the Apellis drug has a chance to upend things. Based on its exciting recent data, Apellis could make a case for pricing at a premium to Soliris. But the smarter course might be to undercut it. Soliris is well-established, and physicians are comfortable with the medicine. They may need an extra nudge to try something new. Alexion already priced Ultomiris at a discount to Soliris to prompt switches. It wouldn’t be surprising if Apellis did the same. Alexion would likely have to respond with discounts to protect its franchise and keep its switch strategy viable. Patients and the health-care system would benefit from both better pricing and an expanded set of options.This scenario could be wishful thinking; after all, pricing in the rare disease space is strange enough that the usual rules of competition might not apply. And there are other examples, especially in oncology, where the entrance of rival medications hasn’t done all that much to lower prices.But here’s hoping anyway that this is a situation where markets work how they should.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2020 Bloomberg L.P.
